Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nuvation Bio (NUVB)
NYSE:NUVB
Holding NUVB?
Track your performance easily
NUVB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.37 - $4.16
Previous Close$2.61
Volume2.40M
Average Volume (3M)1.98M
Market Cap
$881.05M
Enterprise Value$343.11M
Total Cash (Recent Filing)$549.13M
Total Debt (Recent Filing)$11.19M
Price to Earnings (P/E)―
Beta2.58
Next Earnings
Feb 26, 2025EPS Estimate
-$0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.17
Shares Outstanding336,566,525
10 Day Avg. Volume1,948,152
30 Day Avg. Volume1,981,298
Standard Deviation0.21
R-Squared0.11
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.75
Price to Sales (P/S)406.31
Price to Cash Flow (P/CF)-7.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue158.70
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.62
Forecast
1Y Price Target
$6.00Price Target Upside123.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Nuvation Bio News
PremiumCompany Announcements
Nuvation Bio’s Q3 2024 Highlights and Future Prospects
PremiumCompany Announcements
Nuvation Bio Announces Philippe Sauvage as New CFO
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsNuvation Bio's taletrectinib has shown impressive efficacy in ROS1+ non-small cell lung cancer, achieving an 88.8% confirmed objective response rate in treatment-naive patients, positioning it as a strong contender in the cancer treatment landscape.
Market PositionWith its competitive efficacy and safety profile, taletrectinib may become a key player in the ROS1+ NSCLC space, potentially outperforming existing treatments and offering a new hope for patients.
Regulatory ProgressThe planned submission of a New Drug Application for taletrectinib in the U.S. could lead to its potential commercialization, marking a significant step forward in bringing this promising treatment option to patients.
Bears Say
Financial PerformanceAnalyst lowers the 12-month price target to $7 from $8 per share due to higher long-term operating expenses.
Product PerformanceThe drug repotrectinib has seen a slower-than-expected launch likely due to its safety profile, which showed higher neurological adverse effects compared to crizotinib.
Product SafetyTaletrectinib shows elevated rates of gastrointestinal toxicities such as diarrhea, vomiting, and nausea, which are very similar to those of crizotinib.
---
Ownership Overview
27.30% Insiders
10.36% Mutual Funds
27.69% Other Institutional Investors
27.47% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NUVB FAQ
What was Nuvation Bio’s price range in the past 12 months?
Nuvation Bio lowest stock price was $1.37 and its highest was $4.16 in the past 12 months.
What is Nuvation Bio’s market cap?
Currently, no data Available
When is Nuvation Bio’s upcoming earnings report date?
Nuvation Bio’s upcoming earnings report date is Feb 26, 2025 which is in 66 days.
How were Nuvation Bio’s earnings last quarter?
Nuvation Bio released its earnings results on Nov 06, 2024. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.126 by -$0.024.
Is Nuvation Bio overvalued?
According to Wall Street analysts Nuvation Bio’s price is currently Undervalued.
Does Nuvation Bio pay dividends?
Nuvation Bio does not currently pay dividends.
What is Nuvation Bio’s EPS estimate?
Nuvation Bio’s EPS estimate is -$0.14.
How many shares outstanding does Nuvation Bio have?
Nuvation Bio has 336,566,530 shares outstanding.
What happened to Nuvation Bio’s price movement after its last earnings report?
Nuvation Bio reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.126. Following the earnings report the stock price went up 3.15%.
Which hedge fund is a major shareholder of Nuvation Bio?
Among the largest hedge funds holding Nuvation Bio’s share is Omega Fund Management, LLC. It holds Nuvation Bio’s shares valued at 30M.
---
Nuvation Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (123.05% Upside)
$6.00 (123.05% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $57.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
86.42%
12-Months-Change
Fundamentals
Return on Equity
-95.54%
Trailing 12-Months
Asset Growth
-9.40%
Trailing 12-Months
Company Description
Nuvation Bio
Panacea Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
---
NUVB Stock 12 Month Forecast
Average Price Target
$6.00
▲(123.05% Upside)
Technical Analysis
Best Analysts Covering NUVB
1 Year
1 Year Success Rate
5/12 ratings generated profit
1 Year Average Return
+13.84%
reiterated a buy rating 2 months ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +13.84% per trade.
---